{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:38Z","timestamp":1790474138403,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00428-020-02980-9","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T08:11:48Z","timestamp":1610007108000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas"],"prefix":"10.1007","volume":"478","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-6703","authenticated-orcid":false,"given":"Lynnette","family":"Fernandez-Cuesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Mangiante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Alcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"2980_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s1470-2045(13)70257-2","volume":"14","author":"F Baumann","year":"2013","unstructured":"Baumann F, Ambrosi JP, Carbone M (2013) Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol 14:576\u2013578. https:\/\/doi.org\/10.1016\/s1470-2045(13)70257-2","journal-title":"Lancet Oncol"},{"key":"2980_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI (2019) Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69:402\u2013429. https:\/\/doi.org\/10.3322\/caac.21572","journal-title":"CA Cancer J Clin"},{"key":"2980_CR3","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","volume":"11","author":"M Carbone","year":"2016","unstructured":"Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S (2016) Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 11:1246\u20131262. https:\/\/doi.org\/10.1016\/j.jtho.2016.04.028","journal-title":"J Thorac Oncol"},{"key":"2980_CR4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, R\u00f8e OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE (2018) Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol 36:2863\u20132871. https:\/\/doi.org\/10.1200\/jco.2018.78.5204","journal-title":"J Clin Oncol"},{"key":"2980_CR5","doi-asserted-by":"publisher","unstructured":"Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M, Goto K, Goparaju C, Sarin KY, Tanji M, Bononi A, Napolitano A, Gaudino G, Hesdorffer M, Yang H, Carbone M (2018) A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol 36:3485\u20133494. https:\/\/doi.org\/10.1200\/jco.2018.79.0352","DOI":"10.1200\/jco.2018.79.0352"},{"key":"2980_CR6","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"R Hassan","year":"2019","unstructured":"Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE (2019) Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A 116:9008\u20139013. https:\/\/doi.org\/10.1073\/pnas.1821510116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2980_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s10552-009-9357-4","volume":"20","author":"JE Goodman","year":"2009","unstructured":"Goodman JE, Nascarella MA, Valberg PA (2009) Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 20:1237\u20131254. https:\/\/doi.org\/10.1007\/s10552-009-9357-4","journal-title":"Cancer Causes Control"},{"key":"2980_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/modpathol.2017.108","volume":"31","author":"M Vivero","year":"2018","unstructured":"Vivero M, Bueno R, Chirieac LR (2018) Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol 31:122\u2013131. https:\/\/doi.org\/10.1038\/modpathol.2017.108","journal-title":"Mod Pathol"},{"key":"2980_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.5858\/arpa.2017-0537-RA","volume":"142","author":"RL Attanoos","year":"2018","unstructured":"Attanoos RL, Pugh MR (2018) The diagnosis of pleural tumors other than mesothelioma. Arch Pathol Lab Med 142:902\u2013913. https:\/\/doi.org\/10.5858\/arpa.2017-0537-RA","journal-title":"Arch Pathol Lab Med"},{"key":"2980_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/10937404.2016.1195322","volume":"19","author":"F Baumann","year":"2016","unstructured":"Baumann F, Carbone M (2016) Environmental risk of mesothelioma in the United States: an emerging concern-epidemiological issues. J Toxicol Environ Health B Crit Rev 19:231\u2013249. https:\/\/doi.org\/10.1080\/10937404.2016.1195322","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"2980_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/10408440903044928","volume":"39","author":"B Price","year":"2009","unstructured":"Price B, Ware A (2009) Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39:576\u2013588. https:\/\/doi.org\/10.1080\/10408440903044928","journal-title":"Crit Rev Toxicol"},{"key":"2980_CR12","first-page":"5922","volume":"59","author":"A Xu","year":"1999","unstructured":"Xu A, Wu LJ, Santella RM, Hei TK (1999) Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells. Cancer Res 59:5922\u20135926","journal-title":"Cancer Res"},{"key":"2980_CR13","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","volume":"183","author":"F Qi","year":"2013","unstructured":"Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M (2013) Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling. Am J Pathol 183:1654\u20131666. https:\/\/doi.org\/10.1016\/j.ajpath.2013.07.029","journal-title":"Am J Pathol"},{"key":"2980_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.ccr-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone M, Yang H (2012) Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 18:598\u2013604. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-2259","journal-title":"Clin Cancer Res"},{"key":"2980_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/jto.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243\u20131260. https:\/\/doi.org\/10.1097\/jto.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"2980_CR16","doi-asserted-by":"publisher","unstructured":"Nicholson AG, Sauter JL, Nowak A, Kindler H, Gill R, Remy-Jardin M, Armato S, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiolt P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F (2019) EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 15:29\u201349.\u00a0https:\/\/doi.org\/10.1016\/j.jtho.2019.08.2506","DOI":"10.1016\/j.jtho.2019.08.2506"},{"key":"2980_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407\u2013416. https:\/\/doi.org\/10.1038\/ng.3520","journal-title":"Nat Genet"},{"key":"2980_CR18","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.cd-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Salle F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 8:1548\u20131565. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0804","journal-title":"Cancer Discov"},{"key":"2980_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/carcin\/bgz066","volume":"40","author":"H Oey","year":"2019","unstructured":"Oey H, Daniels M, Relan V, Chee TM, Davidson MR, Yang IA, Ellis JJ, Fong KM, Krause L, Bowman RV (2019) Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis 40:724\u2013734. https:\/\/doi.org\/10.1093\/carcin\/bgz066","journal-title":"Carcinogenesis"},{"key":"2980_CR20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel L, Meiller C, Assi\u00e9 JB, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin MC, Hofman V, Gibault L, Badoual C, Pintilie E, Hofman P, Monnet I, Scherpereel A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D (2020) Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol 14:1207\u20131223. https:\/\/doi.org\/10.1002\/1878-0261.12651","journal-title":"Mol Oncol"},{"key":"2980_CR21","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.ccr-13-2429","volume":"20","author":"A de Reyni\u00e8s","year":"2014","unstructured":"de Reyni\u00e8s A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sall\u00e9 F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D (2014) Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20:1323\u20131334. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-2429","journal-title":"Clin Cancer Res"},{"key":"2980_CR22","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/0008-5472.can-05-3907","volume":"66","author":"F L\u00f3pez-R\u00edos","year":"2006","unstructured":"L\u00f3pez-R\u00edos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66:2970\u20132979. https:\/\/doi.org\/10.1158\/0008-5472.can-05-3907","journal-title":"Cancer Res"},{"key":"2980_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","volume":"453","author":"S Dacic","year":"2008","unstructured":"Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H (2008) Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 453:627\u2013635. https:\/\/doi.org\/10.1007\/s00428-008-0689-3","journal-title":"Virchows Arch"},{"key":"2980_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyni\u00e8s A, Jean D (2019) Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun 10:1333. https:\/\/doi.org\/10.1038\/s41467-019-09307-6","journal-title":"Nat Commun"},{"key":"2980_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","volume":"48","author":"N Alcala","year":"2019","unstructured":"Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L (2019) Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine 48:191\u2013202. https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.003","journal-title":"EBioMedicine"},{"key":"2980_CR26","doi-asserted-by":"publisher","unstructured":"Oehl K, Vrugt B, Opitz I, Meerang M (2018) Heterogeneity in malignant pleural mesothelioma. Int J Mol Sci 19:1603. https:\/\/doi.org\/10.3390\/ijms19061603","DOI":"10.3390\/ijms19061603"},{"key":"2980_CR27","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1002\/cncr.32416","volume":"125","author":"LR Chirieac","year":"2019","unstructured":"Chirieac LR, Hung YP, Foo WC, Hofer MD, VanderLaan PA, Richards WG, Sugarbaker DJ, Bueno R (2019) Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer 125:4164\u20134171. https:\/\/doi.org\/10.1002\/cncr.32416","journal-title":"Cancer"},{"key":"2980_CR28","doi-asserted-by":"publisher","first-page":"e1278330","DOI":"10.1080\/2162402x.2016.1278330","volume":"6","author":"K Kiyotani","year":"2017","unstructured":"Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y, Vigneswaran WT (2017) Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology 6:e1278330. https:\/\/doi.org\/10.1080\/2162402x.2016.1278330","journal-title":"Oncoimmunology"},{"key":"2980_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G (2019) Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol 14:276\u2013287. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.001","journal-title":"J Thorac Oncol"},{"key":"2980_CR30","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1158\/1078-0432.ccr-20-1767","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J (2020) Evolution of genomic and T-cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment. Clin Cancer Res 26:5477\u20135486. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-1767","journal-title":"Clin Cancer Res"},{"key":"2980_CR31","doi-asserted-by":"publisher","unstructured":"Felley-Bosco E (2018) Special issue on mechanisms of mesothelioma heterogeneity: highlights and open questions. Int J Mol Sci 19:3560. https:\/\/doi.org\/10.3390\/ijms19113560","DOI":"10.3390\/ijms19113560"},{"key":"2980_CR32","doi-asserted-by":"publisher","unstructured":"Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM (2020) Malignant pleural mesothelioma: genetic and microenviromental heterogeneity as an unexpected reading frame and therapeutic challenge. Cancers (Basel) 12:1186. https:\/\/doi.org\/10.3390\/cancers12051186","DOI":"10.3390\/cancers12051186"},{"key":"2980_CR33","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","volume":"25","author":"P Courtiol","year":"2019","unstructured":"Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N, Girard N, Elemento O, Nicholson AG, Blay JY, Galateau-Sall\u00e9 F, Wainrib G, Clozel T (2019) Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med 25:1519\u20131525. https:\/\/doi.org\/10.1038\/s41591-019-0583-3","journal-title":"Nat Med"},{"key":"2980_CR34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s43018-020-0085-8","volume":"1","author":"Y Fu","year":"2020","unstructured":"Fu Y, Jung AW, Torne RV, Gonzalez S, V\u00f6hringer H, Shmatko A, Yates LR, Jimenez-Linan M, Moore L, Gerstung M (2020) Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat Can 1:800\u2013810. https:\/\/doi.org\/10.1038\/s43018-020-0085-8","journal-title":"Nat Can"},{"key":"2980_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","volume":"1","author":"JN Kather","year":"2020","unstructured":"Kather JN, Heij LR, Grabsch HI, Loeffler C, Echle A, Muti HS, Krause J, Niehues JM, Sommer KAJ, Bankhead P, Kooreman LFS, Schulte JJ, Cipriani NA, Buelow RD, Boor P, Ortiz-Br\u00fcchle N, Hanby AM, Speirs V, Kochanny S, Patnaik A, Srisuwananukorn A, Brenner H, Hoffmeister M, van den Brandt PA, J\u00e4ger D, Trautwein C, Pearson AT, Luedde T (2020) Pan-cancer image-based detection of clinically actionable genetic alterations. Nat Can 1:789\u2013799. https:\/\/doi.org\/10.1038\/s43018-020-0087-6","journal-title":"Nat Can"},{"key":"2980_CR36","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/s0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivi\u00e8re F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405\u20131414. https:\/\/doi.org\/10.1016\/s0140-6736(15)01238-6","journal-title":"Lancet"},{"key":"2980_CR37","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, B\u00f6l\u00fckbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon J-C, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM (2020) ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 55:1900953. https:\/\/doi.org\/10.1183\/13993003.00953-2019","journal-title":"Eur Respir J"},{"key":"2980_CR38","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/s1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C (2018) Novel therapies for malignant pleural mesothelioma. Lancet Oncol 19:e161\u2013e172. https:\/\/doi.org\/10.1016\/s1470-2045(18)30100-1","journal-title":"Lancet Oncol"},{"key":"2980_CR39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/s1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18:623\u2013630. https:\/\/doi.org\/10.1016\/s1470-2045(17)30169-9","journal-title":"Lancet Oncol"},{"key":"2980_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239\u2013253. https:\/\/doi.org\/10.1016\/s1470-2045(18)30765-4","journal-title":"Lancet Oncol"},{"key":"2980_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/s2213-2600(18)30420-x","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P (2019) Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 7:260\u2013270. https:\/\/doi.org\/10.1016\/s2213-2600(18)30420-x","journal-title":"Lancet Respir Med"},{"key":"2980_CR42","doi-asserted-by":"crossref","unstructured":"Baas P, Scherpereel A, Nowak AK (2020) First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743WCLC 2020 Virtual Presidential Symposium on August 8, 2020, Online","DOI":"10.1016\/j.jtho.2020.08.004"},{"key":"2980_CR43","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.ccr-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res 25:5485\u20135492. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-0103","journal-title":"Clin Cancer Res"},{"key":"2980_CR44","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","volume":"15","author":"F Galateau Salle","year":"2020","unstructured":"Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, Brcic L, Capron F, Chirieac LR, Damiola F, Sequeiros R, Cazes A, Damotte D, Foulet A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Paindavoine S, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Brevet M, Rouvier P, Travis WD, Planchard G, Weynand B, Clozel T, Wainrib G, Fernandez-Cuesta L, Pairon JC, Rusch V, Girard N (2020) Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center. J Thorac Oncol 15:1037\u20131053. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.025","journal-title":"J Thorac Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-020-02980-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T08:08:54Z","timestamp":1624867734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-020-02980-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2980"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02980-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"1 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Where authors are identified as personnel of the International Agency for Research on Cancer\/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer\/World Health Organization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}